This inventor holds 1 USPTO granted patent. Top assignee: Mesoblast, Inc. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Andrew Zannetino: Innovator in Mesenchymal Precursor Cell Enrichment
Introduction: Andrew Zannetino is a notable inventor based in South Australia, known for his significant contribution to the field of regenerative medicine. With one patent to his name, Zannetino has made strides in the understanding and application of mesenchymal precursor cells.
Latest Patents: Zannetino's patent focuses on a method of enriching mesenchymal precursor cells. This innovative approach involves the selection of cells based on at least two specific markers. These markers can either be the presence of those unique to mesenchymal precursor cells, the absence of markers specific to differentiated mesenchymal cells, or varying expression levels of specific markers related to mesenchymal precursor cells. The patented method includes a detailed sorting process, utilizing Magnetic Activated Cell Sorting (MACS) to identify STRO-1 antigen expression, followed by a two-color fluorescence-activated cell sorting (FACS) to evaluate high-level STRO-1 expression along with VCAM-1 expression.
Career Highlights: Zannetino is currently employed by Mesoblast, Inc., a renowned company in the field of regenerative medicine, where he applies his expertise to further develop innovative therapies. His work is pivotal in advancing treatments that leverage stem cell biology for various medical applications.
Collaborations: During his professional journey, Zannetino has collaborated with esteemed colleagues such as Paul J Simmons and Stan Gronthos, who share a dedication to exploring and expanding the possibilities within stem cell research and application.
Conclusion: Andrew Zannetino's contributions to the field of regenerative medicine through his patent on mesenchymal precursor cell enrichment exemplify the importance of innovation in driving advancements in healthcare. His ongoing work at Mesoblast, Inc. and collaborations with fellow experts illustrate a commitment to enhancing medical science and improving patient outcomes through innovative therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile